Hubert L Allen sold $18M of ABT
EXECUTIVE VICE PRESIDENT at ABBOTT LABORATORIES. 157,421 shares at an average of $117.04, traded Oct 21, 2024, filed Oct 23, 2024.
Score components
- +15RoleOfficer
- +25Trade size$18.4M at market
- +10Share of holdings soldSold 46% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +0.6%, 3m +1.2%, 6m +12.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-025575, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 21, 2024 | MOption exercise Common shares without par value10b5-1 | +157,421 | $47.00 | $7.4M | 342,227 | Oct 23, 2024 |
| Oct 21, 2024 | SOpen-market sale Common shares without par value10b5-1 | -1,249 | $118.81 | $148k | 340,978 | Oct 23, 2024 |
| Oct 21, 2024 | SOpen-market sale Common shares without par value10b5-1 | -5,901 | $118.15 | $697k | 335,077 | Oct 23, 2024 |
| Oct 21, 2024 | SOpen-market sale Common shares without par value10b5-1 | -150,271 | $116.98 | $18M | 184,806 | Oct 23, 2024 |
| Oct 21, 2024 | MOption exercise Option (right to buy)derivative10b5-1 | -157,421 | $0.00 | $0 | 0 | Oct 23, 2024 |
Related signals
Other insiders at ABBOTT LABORATORIES and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | ABTsell ABBOTT LABORATORIES | John A. McCoy Jr. VICE PRESIDENT AND CONTROLLER | $2,958 27 shares | -0% | |
| 30Weak | ABTsell ABBOTT LABORATORIES | Sally E. Blount director | $337k 2,600 shares | -7% | |
| 60Notable | ABBOTT LABORATORIES | Lisa D Earnhardt EVP AND GROUP PRESIDENT | $12M 91,367 shares | -56% | |
| 49Moderate | ABBOTT LABORATORIES | John A. McCoy Jr. VICE PRESIDENT AND CONTROLLER | $78k 562 shares | -3% | |
| 50Moderate | ABBOTT LABORATORIES | Mary K Moreland EXECUTIVE VICE PRESIDENT | $109k 791 shares | -1% | |
| 51Moderate | ABBOTT LABORATORIES | Louis H. Morrone EXECUTIVE VICE PRESIDENT | $154k 1,111 shares | -2% | |
| 39Weak | ABBOTT LABORATORIES | Eric Shroff Senior Vice President | $78k 562 shares | -2% | |
| 41Moderate | ABBOTT LABORATORIES | Andrea F Wainer RETIRED EVP | $131k 949 shares | -1% | |
| 70Notable | ABBOTT LABORATORIES | Robert B Ford CHAIRMAN AND CEO | $37M 285,388 shares | -56% | |
| 45Moderate | ABBOTT LABORATORIES | Daniel Gesua Sive Salvadori EXECUTIVE VICE PRESIDENT | $3.1M 23,771 shares | -16% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.